The Bcr-Abl fusion gene encodes for the p210 Bcr-Abl or p185 Bcr-Abl tyrosine kinase (TK) implicated in the pathogenesis of chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia, respectively. Because Bcr-Abl TK is chaperoned by Hsp90 (90 kDa heat-shock protein), we investigated the effects of novobiocin (NB), an Hsp90 C-terminal inhibitor, on the viability of the Bcr-Abl-positive human leukemia cells HL-60/Bcr-Abl and K562, the expression of Bcr-Abl protein and the interaction between Hsp90 and Bcr-Abl TK. Present studies demonstrate that NB is a potent inhibitor of the growth of Bcr-Abl-positive human leukemia cells. NB induces cytosolic accumulation of cytochrome c and activation of caspase-9 and caspase-3, triggering apoptosis of HL-60/Bcr-Abl and K562 cells. Treatment of cell lines with NB disrupts Bcr-Abl /Hsp90 and Bcr-Abl /Hsp70 interactions, resulting in a decreased amount of intracellular Bcr-Abl protein levels. Co-treatment with the proteasome inhibitor N-acetyl leucyl-leucyl norlucinal increases NB-mediated accumulation of Bcr-Abl in the detergent-insoluble cellular fraction, which demonstrates that NB promotes proteasomal degradation of Bcr-Abl. Moreover, both imatinib-resistant K562/G01 and primary CML CD34 þ cells are sensitive to NB.
Introduction
Molecular chaperones have many functions, such as protecting other proteins against aggregation, assisting in folding of nascent proteins/refolding of damaged proteins and targeting severely damaged proteins to degradation. As one of the molecular chaperones, Hsp90 functions to facilitate the folding of newly synthesized and denatured client proteins, including mutated p53, Bcr-Abl, p185 ErbB2 and Raf-1. [1] [2] [3] Many of these client proteins are in proliferation signaling pathways, which are often important in many types of cancers. Furthermore, this makes Hsp90 especially promising as a target for anticancer drugs as the ability of Hsp90 inhibitors alters the activity of multiple aberrant signaling molecules instead of just one or two. Functional analysis has revealed that Hsp90 contains two distinct chaperone sites, one in the N terminus and one in the C terminus of the protein. 4, 5 Both N-and C-terminal domains of Hsp90 interact with co-chaperones or ATP and then modulate chaperone activity. Geldanamycin (GA), one of the typical Hsp90 inhibitors, interacts with the N-terminal nucleotidebinding site on Hsp90, leading to alterations in the conformation and function of client proteins including Bcr-Abl. 6, 7 In contrast to GA, novobiocin (NB), a member of the coumermycin family of antibiotics, interacts with the C-terminal region of Hsp90, resulting in depletion of several oncogenic protein kinases, including v-Src, Raf-1 and p185 ErbB28 by disrupting the chaperone activity of Hsp90. 9 The Bcr-Abl fusion gene encodes for the p210 BcrÀAbl or p185 BcrÀAbl tyrosine kinase (TK) implicated in the pathogenesis of chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL), respectively. 10 Studies in cultured cells have identified many signal transduction pathways activated by Bcr-Abl, including activation of the Ras, MAPK, JNK/SAPK, phosphatidylinositol-3 kinase, nuclear factor-kB and STAT pathways. Studies with inhibitors and dominant-negative mutants have suggested that several of these pathways contribute to transformation of hematopoietic cells by Bcr-Abl in vitro. 10 Because Bcr-Abl is one of the client proteins of Hsp90, 11, 12 disruption chaperone functions of Hsp90 may reduce the protein level of Bcr-Abl, and therefore potentially retard several signal transduction pathways initiated by Bcr-Abl. Will the Hsp90 C-terminal inhibitor NB deplete Bcr-Abl proteins, then arrest signaling pathways initiated by it, resulting in inhibition of Bcr-Abl-positive CML cells?
In an effort to test the effects of NB on Bcr-Abl expressing cells as well as the relationship between these effects and the molecular chaperone functions of Hsp90, we investigated the effects of NB on the proliferation viability and induction of apoptosis in the Bcr-Abl-positive human leukemia cells HL-60/Bcr-Abl and K562 cells with ectopic and endogenous expression of Bcr-Abl TK, the expression of Bcr-Abl kinase protein, and the interaction between Hsp90 and Bcr-Abl kinase. The proteasome inhibitor N-acetyl leucyl-leucyl norlucinal (ALLnL) was used to determine the downregulation pathway of Bcr-Abl. If NB is able to inhibit the growth of leukemia cells by disruption of Hsp90 molecular chaperone functions, it may be sensitive to imatinib (STI571)-resistant, Bcr-Abl-positive leukemia cells, as resistance to imatinib may develop mainly due to overexpression of Bcr-Abl. 13, 14 To confirm this idea, the effects of NB on imatinib-resistant K562 cells, K562/G01, were identified. These studies demonstrate for the first time the activity of NB against Bcr-Abl-positive leukemia cells and suggest that destruction of Hsp90 chaperone function, resulting in disruption the combination of Bcr-Abl with Hsp90 and cochaperones and induction of proteasomal degradation of Bcr-Abl, may be an important mechanism of NB-mediated effects on leukemic blasts.
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Materials and methods
Reagents
NB and ALLnL were purchased from Sigma Chemical Co. (St Louis, MO, USA). STI571 was kindly provided by Novartis Pharma AG (Basel, Switzerland). GA, anti-Hsp90, anti-Hsp70 or anti-caspase-9 antibodies were purchased from StressGen Biotechnologies Corp. (Victoria, British Columbia, Canada). Protein G agarose beads, anti-cytochrome c, anti-AKT, anti-p-Akt(ser473), anti-ERK2, anti-p-ERK2 and anti-procaspase3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Caspase 9/3 activity assay kits were purchased from Nanjing keygen Biotech Co. Ltd, China.
Cell culture
HL-60, K562, MEG-01, Dami, NB4 and 6T-CEM leukemia cell lines were obtained from Shanghai Cell Bank of the Chinese Academy of Sciences. The HL-60/Bcr-Abl cell line was kindly provided by Dr Kapil Bhalla (Interdisciplinary Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA 12 ). The imatinib-resistant K562/G01 cell line was kindly provided by Professor Chunzheng Yang (Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 15 ) The human leukemic cell lines were maintained in RPMI1640 supplemented with 10-20% fetal calf serum and grown in a 5% CO 2 atmosphere at 37 1C. K562/G01 cells were maintained in RPMI1640 containing or lacking 4 mM imatinib.
Bone marrow samples were obtained with informed consent from six patients with CML and from six patients with nonmyeloid hematologic disorders (for example, iron deficiency and thrombocytopenia). CD34 þ cells were enriched as described. 16 CD34 þ cell purity was always greater than 90% as determined by flow cytometric analysis.
Clonogenic assays
CD34 þ cells, cultured for 48 h alone or in the presence of inhibitors, were plated in methylcellulose progenitor culture for 14 days and assessed for the presence of colony-forming units (CFU). 17 
Cell proliferation assays
Cell proliferation was measured either by counting viable cells by Trypan blue exclusion or by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Company) colorimetric dye-reduction method. All experiments were repeated at least twice in triplicate. The drug concentration resulting in 50% inhibition of growth (IC 50 ) was determined.
Apoptosis assessment by annexin V staining
Cells were resuspended in staining solution containing annexin V fluorescein and propidium iodide (PI), and then analyzed using flow cytometry. Cells that stained negatively for both PI and annexin V were scored as viable, cells with high PI staining and low annexin V staining were scored as having died through a nonapoptotic mechanism, whereas annexin V-positive cells and PI-negative cells were scored as early apoptotic cells, and annexin V-and PI-positive cells were scored as late apoptotic cells. 20 Assay for cytochrome c release Cells were lysed and then centrifuged to pellet nuclei and unbroken cells. Supernatants were collected and centrifuged at 100 000 g for 30 min at 4 1C (S-100, cytosolic fraction). The resulting mitochondrial pellets were resuspended in lysis buffer (mitochondrial fraction). From this, 30 mg of proteins from the cytosolic and mitochondrial fractions of each sample were analyzed by immunoblotting using an anti-cytochrome c antibody. 18 Caspase 9/3 activity assay Cell lysates were prepared, and assays were performed by incubating cell lysates in reaction buffer containing the caspase 9/3 substrates (caspase 9/3 activity assay kits). Lysates were incubated at 37 1C for 4 h in triplicate wells; thereafter, the absorbance at 405 nm was measured with a spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA).
Immunoprecipitation and immunoblotting analyses
Protein G agarose beads were washed and then incubated with anti-Abl or anti-Hsp90 monoclonal antibody (mAb) at 4 1C for 2 h. After washing the protein G and the antibodies, total cell lysates were added and incubated overnight at 4 1C. The immunoprecipitates were washed, and proteins were eluted with the SDS sample-loading buffer. Proteins were separated by SDS-polyacrylamide (PAGE) gels as described. 19 Immunoprecipitates were examined by immunoblotting analysis using anti-Abl, anti-Hsp90, anti-Hsp70 or anti-b-actin mAb according to protocols reported previously.
Preparation of detergent-soluble and -insoluble fractions
Cells were lysed with TNSEV buffer (50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 100 mM NaCl, 1 mM sodium orthovanadate, 1% NP40 containing 20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mM phenylmethylsulphonylfluoride, 25 mM sodium fluoride (NAF) and 5 mM N-ethylmaleimide). NP40 insoluble proteins were solubilized with SDS buffer. From this, 30 mg of proteins from the NP40 soluble and insoluble fraction were separated on 8% SDS-polyacrylamide gels and analyzed by immunoblotting. 12 
Statistical analysis
Results were reported as the mean±s.d. Significance levels were determined by the Student's t-test. Differences were considered significant when Po0.05.
Results
NB induces apoptosis of HL-60/Bcr-Abl and K562 cells
To begin these investigations, viability in response to a range of NB doses was conducted. As shown in Figure 1a , NB was a potent inhibitor of proliferation of Bcr-Abl-expressing cells with IC 50 values of 0.5174 mM in HL-60/Bcr-Abl cells, and 0.4353 mM in K562 cells. NB also inhibited the viability of HL-60, MEG-01, Dami, NB4 and 6T-CEM cells markedly with IC 50 values of 0.3546, 0.3432, 0.3845, 0.5585 and 0.4630 mM, respectively. This result demonstrates that both Bcr-Abl-positive and -negative cells are sensitive to NB. So, unlike other targeted agents, being an Hsp90 C-terminal inhibitor, NB may influence not only one target, but also many other factors that are critical for cancer growth. 
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To evaluate the role apoptosis may be playing in the death of Bcr-Abl-positive human leukemia cells in response to NB, annexin V/PI staining, cytochrome c release and activation of caspase-9/3 were examined. Co-staining with annexin V and PI allows segregation of viable, apoptotic and necrotic cell populations based on the characteristics and integrity of the extracellular membrane to these dyes. 21 Figure 1c demonstrated that treatment with 0.3 mM NB, 0.6 mM NB or 5 mM GA induced apoptosis of both HL-60 and HL-60/Bcr-Abl cells. A concentration-dependent increase in apoptosis attributable to NB was observed in HL-60/Bcr-Abl cells (Figure 1c ). However, in HL-60 cells, 0.6 mM NB induced less apoptosis and more nonapoptotic cell death than 0.3 mM NB. In addition, an apparent discrepancy was noted between the total amount of cell death observed in our viability assays and the quantified levels of apoptotic cells in populations of treated leukemia cells. For example, 24 h after treatment with 0.6 mM NB, we observed that approximately 80% of HL-60 and 56% of HL-60/Bcr-Abl cells were nonviable as measured by MTT. However, we observed that a significantly lower percentage of similarly treated HL-60 or HL-60/Bcr-Abl cells stain positively for annexin V at these time points. Given these observations, we reasoned that NB was activating another cell death mechanism in these cells. The mechanism(s) was not determined in the present studies.
Because Bcr-Abl expression inhibits the cytosolic accumulation of cytochrome c induced by apoptotic stimuli, 22 we examined whether NB-induced apoptosis of HL-60/Bcr-Abl or K562 cells was associated with cytosolic accumulation of cyt c and the subsequent processing of caspase-9 and caspase-3. Figure 2a demonstrated that treatment with NB induced cytochrome c release from the mitochondrion to cytoplasm both in Bcr-Abl-negative HL-60 cells and Bcr-Abl-positive cells, and caspase 9/3 activity markedly increased ( Figure 2 ). Moreover, the procaspase-3 level was decreased after NB or GA treatment, which implied that procaspase-3 was activated and cleaved into active fragments.
NB reduces Bcr-Abl levels and lowers ERK and AKT kinase activity
Because Bcr-Abl mediates resistance to chemotherapeutic agents, we examined whether NB-induced cell death was associated with the lowering of Bcr-Abl levels. Immunoblotting analysis demonstrated that exposure to NB or GA for 24 h decreased Bcr-Abl protein content markedly in HL-60/Bcr-Abl and K562 cells (Figure 3 ). NB and GA also downregulated the levels of p-AKT and p-ERK in Bcr-Abl-positive cells and control HL-60 cells ( Figure 3 ). Lowering of ERK and AKT kinase activity may be promoting NB-and GA-induced apoptosis of HL-60 cells and contributing to the decline in Bcr-Abl levels in HL-60/ Bcr-Abl and K562 cells.
NB causes decreased binding of Bcr-Abl to Hsp90 and Hsp70
To determine whether reduction of Bcr-Abl protein content induced by NB resulted, at least partially, from disruption of Hsp90 chaperone function, we first examined the level of heatshock related proteins in cells after treatment with NB. Figure 4a showed that both Hsp27 and Hsp70 were induced by treatment with 5 mM GA for 24 h; in contrast, NB had no influence on Hsp27 and Hsp70 protein levels. Thus, NB has an advantage over GA. Due to the fact that increased hsp70 levels inhibit death receptor and mitochondria-initiated signaling for apoptosis, 23, 24 GA would induce chemotherapy resistance for its Hsp70-induced effects. Hsp90 and p23 were not affected by NB or GA in HL-60, HL-60/Bcr-Abl or K562 cells. P60Hop, which preferentially binds the ADP-bound conformations of Hsp90 and Hsp70, stabilizes the interaction of Hsp90 with the Hsp70receptor heterocomplex 25, 26 was reduced by 0.6 mM NB. We next carried out co-immunoprecipitation experiments to investigate the effects of NB on Hsp90/Bcr-Abl protein interactions (Figures 4b and c ). K562 and HL-60/Bcr-Abl cells were treated with 0.3 mM NB, 0.6 mM NB or 5 mM GA for 6 h, an exposure interval during which Bcr-Abl levels were not affected. Cell lysates were obtained at 6 h, and incubated with anti-Abl mouse antiserum and protein G beads to immunoprecipitate Bcr-Abl. After western blot transfer, the membranes were blotted with anti-Abl, anti-Hsp90 or anti-Hsp70 antibodies, respectively. Figure 4b , demonstrates that approximately equal amounts of Bcr-Abl were precipitated under each condition.
Hsp90 and Hsp70 were co-precipitated with Bcr-Abl kinase in K562 and HL-60/Bcr-Abl cells, which confirmed the association of the Bcr-Abl with Hsp90 and Hsp70 in both K562 and HL-60/ Bcr-Abl cells. Treatment with NB or GA significantly reduced amounts of Hsp90 that were co-precipitated with Bcr-Abl in both cell lines. To exclude the possibility that the apparent decrease of Hsp90 association with Bcr-Abl kinase was merely the result of decreased overall Bcr-Abl protein, an exposure interval of 6 h was chosen, during which Bcr-Abl levels were not affected (data not shown).
Alternatively, we further determined whether antibodies to Hsp90 could immunoprecipitate Bcr-Abl and whether NB disrupted the interaction. Immunoprecipitation was performed using an anti-Hsp90 antibody and cell lysates from K562 and HL-60/Bcr-Abl cells were treated with NB 0.3 mM, 0.6 mM or GA 5 mM for 6 h (Figure 4c ). Similar amounts of Hsp90 were recovered under each condition. Bcr-Abl was co-precipitated with Hsp90 in controls, but was absent in the immune complex from NB-treated cell lysates. Figure 4b shows that, as compared with untreated cells, in cells treated with NB there was a gradual decline in the association of Bcr-Abl with Hsp70, as well as Hsp90. This loss in Bcr-Abl-associated Hsp90 and Hsp70 occurred before any detectable loss in the levels of Bcr-Abl attributable to treatment with NB. Unlike GA, NB was not able to increase the association of Bcr-Abl with Hsp70. Thus, NB, besides mimicking the biological effects of GA, may have an additional negative impact on Hsp90 function, although this hypothesis remains to be examined.
NB treatment promotes proteasomal degradation of Bcr-Abl in K562 cells
Previous studies have demonstrated that the GA-induced disruption of binding of Hsp90 with v-src, Raf-1 and Bcr-Abl directs these proteins for degradation by proteasomes, which can be inhibited by proteasome inhibitors. 11, 12 Therefore, we investigated whether the NB-mediated decline in Bcr-Abl levels was attributable to degradation by the proteasomes. Figure 5 demonstrates that treatment with NB for 24 h alone depleted the levels of Bcr-Abl in the detergent (NP40)-soluble fraction, whereas increasing its levels in the detergent (NP40)-insoluble cellular fraction, prior to degradation by the proteasome. Consistent with this, co-treatment with the proteasome inhibitor ALLnL increased NB-mediated accumulation of Bcr-Abl in the detergent-insoluble cellular fraction. Similar effects of NB were also observed in HL-60/Bcr-Abl cells (data not shown). Collectively, these data indicate that treatment with NB disrupted the stable chaperone association of Bcr-Abl with Hsp 90, which promotes proteasomal degradation of Bcr-Abl.
NB inhibits the proliferation of imatinib-resistant K562 cells involving depletion of Bcr-Abl protein
Imatinib mesylate is effective as a single-agent therapy for CML. However, resistance is universal and clinical relapse develops rapidly in the advanced phases of CML. This resistance has been shown to be caused by specific ATP-binding site mutations or amplification of the Bcr-Abl gene. Novel TK inhibitors that target Bcr-Abl TK, or agents that downregulate Bcr-Abl levels, may need to be developed for the future therapy of imatinib-resistant CML. As shown above, NB is able to downregulate Bcr-Abl levels dramatically. Therefore, we first determined the cytotoxic effects of this novel anti-Bcr-Abl agent against imatinib-resistant K562 cells (K562/G01). K562 cells were cultured in gradually increasing concentrations of imatinib over a period of several months, generating the resistant line K562/G01, which was established with 15.2-fold resistance to imatinib as compared with that of the parental sensitive cell line. 15 The mechanisms of resistance of K562/G01 cells to imatinib involved amplification of the bcr-abl fusion gene (Figure 6a ), increased expression of Bcr-Abl (Figure 6c ), and increased tyrosine activity of the Bcr-Abl protein (Figure 6c ). 15 Figure 6b shows that NB was a potent inhibitor of proliferation of K562 and K562/G01 cells with IC 50 values of 0.4353 mM and 0.3490 mM, respectively. Figure 6c showed that NB 0.6 mM downregulated Bcr-Abl and p-tyrosine levels markedly in both K562/G01 cells and K562 cells. In contrast, STI571 was unable to downregulate Bcr-Abl levels in these two cell lines. Combination of treatment with NB and STI571 resulted in a dramatic depletion of p-tyrosine. This result demonstrated that NB inhibits imatinib-resistant and -sensitive cells involving downregulation of Bcr-Abl.
NB inhibits the proliferation of CD34 þ cells from CML patients
To determine whether these events could be extended to primary CD34 þ CML cells and whether NB is more sensitive to CD34 þ cells from CML patients than from healthy donors, CD34 þ cells were isolated, and their growth inhibitory and apoptotic effects were tested. It was significant that treatment with NB 0.1 mM resulted in a marked suppression by 64.3% in colony formation of CD34 þ CML cells (Figure 7b ). A clear increase in apoptosis (57.1%) was also observed after treatment with NB 0.4 mM for 24 h in CD34 þ cells obtained from CML patients (Figure 7d ). In contrast, NB exerted relatively little toxicity toward normal bone marrow CD34 þ cells isolated from (Figure 7 ). After treatment with NB 0.1 mM, colony suppression was only 2.5%, and treatment with NB 0.4 mM for 24 h, the apoptotic cells were 15.57% in normal CD34 þ cells.
Thus, primary CD34 þ CML cells, like other leukemia cells, were sensitive to NB. Furthermore, NB has some selectivity between normal and CML CD34 þ cells. 
Discussion
Present studies demonstrate that treatment with NB depletes Bcr-Abl and induces apoptosis and nonapoptotic cell death in HL-60/Bcr-Abl and K562 cells. Bcr-Abl activates diverse molecular mechanisms known to inhibit apoptosis in CML-BC and Bcr-Abl-positive ALL cells. Our results clearly indicate that by lowering Bcr-Abl and Akt kinase activity, NB induces release of cytochrome c, and then cytochrome c complexes with the protein apaf-1 permitting it to bind procaspase-9, which promotes autocleavage and consequential activation of caspase-9. Activation of caspase-9, in turn, leads to cleavage/ activation of the executioner caspase-3 that ultimately promotes apoptosis by cleaving a wide spectrum of specific substrates.
As compared with GA, NB would not induce the expression of Hsp70 in HL-60/Bcr-Abl and K562 cells. Several reports have documented that Hsp70 inhibits the mitochondrial pathway of apoptosis. 24 Additionally, Hsp70 contributes to Bcr-Ablmediated resistance to apoptosis due to antileukemia agents. 24 Conversely, Hsp70 depletion has been shown to induce apoptosis. 24 On the basis of these findings, NB has an advantage over GA.
Hsp90 is largely in a latent, uncomplexed state in normal cells. However, Hsp90 becomes activated, forming a large complex with various co-chaperones, including Hsp70, p60Hop, cyclophilin 40 and p23, in tumor cells. 11 Our data indicate that treatment with NB disrupts binding of Hsp90 with both Bcr-Abl TK and Hsp70, which is different from GA, which disrupts binding of Hsp90 with Bcr-Abl TK, while promoting its chaperone association with Hsp70. Similar to GA, NB also promotes the degradation of Bcr-Abl TK by proteasomes. Nimmanapalli's group has shown that co-treatment with the proteasome inhibitor PS341 not only inhibits the 17-AAG (a clinically relevant analogue of GA)-mediated decline in Bcr-Abl levels, but also inhibits 17-AAG-induced apoptosis of HL-60/ Bcr-Abl and K562. 12 However, unlike in their report, co-treatment with the proteasome inhibitor ALLnL is not able to inhibit NB-induced cell death of HL-60/Bcr-Abl and K562 (data not shown). Thus, NB, besides mimicking the biological effects of GA may have an additional negative impact on Hsp90 function.
In the present study, our data demonstrate that NB also lowers Bcr-Abl levels and TK activity in imatinib-resistant K562/G01 cells. Furthermore, NB is a well-studied antibiotic, whose pharmacokinetics and toxicity profiles are clearly understood. In humans, doses of 4 g per day yield a plasma level of 200-300 mg/ml or higher, and 2 h after oral administration yield a drug concentration of 0.3-0.5 mM, 27 at which concentrations NB can deplete Bcr-Abl in human CML cells. Moreover, Burlison and co-workers developed a library of NB analogues to prepare more efficacious inhibitors of the Hsp90 C-terminal binding site. 28 Collectively, the findings will support the in vivo studies of NB against Bcr-Abl-positive human leukemias that are either sensitive or resistant to imatinib. Using NB or analogous compounds in combination with imatinib may be useful to overcome resistance in the clinical setting. 
